Tissue & Repair

BPC-157

Price range: $35.99 through $54.99

Current Lot WWB-BC5-7131 verified Mar 3, 2026

Synthetic pentadecapeptide

CAS Number
137525-51-0
Molecular Formula
C₆₂H₉₈N₁₆O₂₂
Molecular Weight
1419.55 g/mol
Form
Lyophilized
Purity
≥99.4% by HPLC-UV
Cold-Packed Protected seasonal packaging
Dispatches ≤48hr From Columbia, SC
Lot Verified COA included with every order
Independently Tested HPLC-UV verified, every single lot
Lot-traceable — matched to a public Certificate of Analysis
Research Use Only — not for human or veterinary use
View Certificate of Analysis

What You Receive

1× Research Vial
  • BPC-157 — nominal content per selected size
  • Lyophilized
  • Tamper-evident seal
  • Lot-numbered label
  • Lot-matched Certificate of Analysis
Verification

Current Lot & Certificate of Analysis

Lot NumberWWB-BC5-7131
HPLC Purity99.11%
Test DateMar 3, 2026
Testing LaboratoryColmaric Analyticals
Analytical MethodHPLC-UV, 218nm
LC-MS IdentityConfirmed
Specifications

Technical Specifications

CAS Number 137525-51-0
Molecular Formula C₆₂H₉₈N₁₆O₂₂
Molecular Weight 1419.55 g/mol
Physical Form Lyophilized
Purity Specification ≥99.4% by HPLC-UV
Analytical Method HPLC-UV, 218nm
Appearance Lyophilized research peptide
Storage Conditions Store sealed, protected from moisture and light; minimize temperature cycling
Lot Number WWB-BC5-7131
Batch / Test Date Mar 3, 2026
Research Context

Research Overview

BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of body protection compound, a protein identified in human gastric juice. It is composed of fifteen amino acids and is described in the literature as a stable gastric pentadecapeptide, a designation reflecting its reported resistance to degradation in gastric conditions relative to many peptides of comparable size.

Mechanistic context

The published mechanistic work centres on angiogenesis and cellular migration rather than on a single identified receptor. No canonical receptor has been established for BPC-157 in the peer-reviewed record, which distinguishes it from compounds such as ipamorelin or kisspeptin where the binding target is defined. Investigations have instead examined effects on granulation tissue formation, new vessel development, and the behaviour of tendon-derived cells in culture. This is an important interpretive point: the literature describes observed tissue-level and cellular effects without resolving the upstream molecular pathway.

Published findings

Sikiric and colleagues (1999) examined effects on new vessel and granulation tissue formation, comparing the pentadecapeptide against H2-blockers, omeprazole and sucralfate — a design that situates it against established agents rather than against vehicle alone.

Staresinic and colleagues (2003) reported accelerated healing of transected rat Achilles tendon and, in parallel, stimulation of tendocyte growth in vitro. The pairing of an in vivo transection model with a cell culture arm is characteristic of this literature and allows tissue-level observations to be linked to a cellular readout.

Brcic and colleagues (2009) examined the modulatory effect on angiogenesis specifically in muscle and tendon healing. Chang and colleagues (2011) reported that the promoting effect on tendon healing involved tendon outgrowth, cell survival and cell migration, identifying the cellular processes through which the tissue-level observations may arise.

Scope and limitations of the evidence

The BPC-157 literature is preclinical in its entirety. The findings summarised here derive from rat models and cultured cells; no controlled human trial literature establishes effects in people. A substantial share of the published work originates from a small number of collaborating research groups, which bears on the weight that independent replication can carry.

The absence of an identified receptor is the most significant methodological limitation. Without a defined molecular target, it is difficult to demonstrate target engagement, to design competitive antagonist controls, or to distinguish specific activity from non-specific effects on wound environments. Investigators working with the compound should treat mechanistic statements in secondary sources with caution, as these frequently outrun what the primary literature establishes.

Use in experimental design

Tendon and muscle healing models are sensitive to surgical technique, animal age and immobilisation protocol, and these variables differ across the cited studies. Comparisons between reports should account for them. Where cell culture arms are used, the distinction between proliferation, migration and survival endpoints matters, since Chang and colleagues identified all three as contributing and they are not interchangeable measures.

Analytical and handling notes

Each lot is supplied with a certificate of analysis reporting RP-HPLC purity, mass identification by ESI-MS and label claim recovery, together with an independent ICP-MS elemental impurities report. Purity figures apply to the specific lot tested and should be read against the lot documentation rather than inferred from generic reference material. Storage guidance appears on the technical data sheet; the exact supplied salt form, counterion and hydration state are lot and supplier specific and should be reconciled against supplier documentation before quantitative work.

This material is supplied for laboratory research use only. It is not a drug, is not intended for human or veterinary use, and no statement above should be read as a claim of therapeutic effect.

References

  1. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4.
  2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010.
  3. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009;60 Suppl 7:191-196. PMID:20388964.
  4. Sikiric P, Separovic J, Anic T, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. J Physiol Paris. 1999;93(6):479-485. doi:10.1016/S0928-4257(99)00123-0.

Citations are provided for research context only. They describe published work on this compound and are not claims about this product.

Fulfillment

Fulfillment & Packaging

Ships From

Columbia, South Carolina

Dispatch Timeframe

Within 48 hours of order confirmation

Cold-Chain Packaging

Insulated, seasonally adjusted packaging protects material in transit

Tamper-Evident Vial

Every vial ships sealed and lot-labeled

Shipping Area

Domestic (U.S.) shipping only

Shipping Cost

Calculated at checkout — see the Shipping Policy for full details

Questions

Frequently Asked Questions

Is this lot independently tested?

Yes. Every lot is tested by an independent third-party laboratory using HPLC-UV before it is released for sale, and results are published in the COA Library.

How do I locate my lot's Certificate of Analysis?

Use the "View Certificate of Analysis" link on this page, or search the COA Library directly by compound name or the lot number printed on your vial label.

What analytical methods are used?

Purity is determined by HPLC-UV. Molecular identity is confirmed by LC-MS prior to release.

How is the material packaged?

Material ships in a tamper-evident, lot-labeled vial inside cold-chain packaging appropriate for the season.

What does "Research Use Only" mean?

This product is sold exclusively for laboratory and in-vitro research applications by qualified researchers. It is not a drug, dietary supplement, or approved for human or veterinary use.